It all started in 2018 with a group of people dog lovers talking on Facebook about the need for a dog park in York. Their conversation led to the creation of a Facebook group, where additional town residents and visitors voiced their support for the park. A small group of individuals from the group decided to meet and eventually formed a committee and went to work on putting their idea into motion.
Friends of York Dog Park is now a 501 (c) 3 nonprofit organization comprised of York residents with a mission to develop and maintain a community dog park that provides a safe and controlled environment where dogs and their owners can meet.
Atsena Therapeutics, a Durham, N.C. and Boston, MA-based clinical-stage gene therapy company, closed a $55m Series A financing.
The round was led by Sofinnova Investments with participation from additional new investors Abingworth and Lightstone Ventures and founding investors Hatteras Venture Partners and the Foundation Fighting Blindness’ RD Fund, and existing investors Osage University Partners, University of Florida, and Manning Family Foundation. In conjunction with the funding, Sarah Bhagat, PhD, Partner at Sofinnova, Jackie Grant, PhD, Principal at Abingworth, and Jason Lettmann, General Partner at Lightstone, will join Atsena’s board of directors.
The company intends to use the funds to:
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical .
Atsena TherapeuticsDecember 16, 2020 GMT
Round was led by Sofinnova Investments with participation from Abingworth, Lightstone Ventures and all existing investors
Company expands board of directors and plans to build out team
DURHAM, N.C. and BOSTON, Dec. 16, 2020 (GLOBE NEWSWIRE) Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced it has closed an oversubscribed $55 million Series A financing led by Sofinnova Investments with participation from additional new investors Abingworth and Lightstone Ventures. Founding investors Hatteras Venture Partners and the Foundation Fighting Blindness’ RD Fund, along with existing investors Osage University Partners, University of F
(YaroslavKryuchka/Getty Images)
University of Florida (UF) spinout Atsena Therapeutics has closed a $55 million financing that will help take its gene therapy for a common cause of blindness in children into pivotal trials.
The gene therapy is already in a phase 1/2 trial for Leber congenital amaurosis (LCA) a disease that progressively destroys the retina in patients with a mutation in the GUCY2D gene. Atsena acquired the candidate from Sanofi earlier this year, which in turn licensed it from UF.
The Durham, North Carolina-based biotech is hoping to follow in the footsteps of Spark Therapeutics (now part of Roche), whose Luxturna became the first directly administered gene therapy to be approved in the U.S. in 2017.
Published: Dec 16, 2020
DURHAM, N.C. and BOSTON, Dec. 16, 2020 (GLOBE NEWSWIRE) Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced it has closed an oversubscribed $55 million Series A financing led by Sofinnova Investments with participation from additional new investors Abingworth and Lightstone Ventures. Founding investors Hatteras Venture Partners and the Foundation Fighting Blindness’ RD Fund, along with existing investors Osage University Partners, University of Florida, and Manning Family Foundation, also participated in the round. Sarah Bhagat, PhD, Partner at Sofinnova, Jackie Grant, PhD, Principal at Abingworth, and Jason Lettmann, General Partner at Lightstone, will join Atsena’s board of directors.